MedPath

Comparing the immune response between kidney transplant recipients with standard immunosuppressive regimen vs mycophenolic acid sparing regimen after extended primary series of two doses of Chadox-1 and single dose of BNT-162b2.

Recruiting
Conditions
immunological response after the booster dose of vaccine is given.
covid vaccine
kidney transplant
BNT162b2
Registration Number
TCTR20220402001
Lead Sponsor
/A
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
113
Inclusion Criteria

post kidney transplant > 6 months
post ChAdOx-1 2 dosesage 18-70 YO

Exclusion Criteria

recently renal graft rejection
active CMV, BK viremia, infection
active malignancy
pregnancy and breast feeding
past COVID infection

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
anti SARS-CoV2 S antibody 4 weeks Elecsys, by Cobas e 411 analyzer; Roche Diagnostics, Basel, Switzerland
Secondary Outcome Measures
NameTimeMethod
anti HLA antibody 4 weeks PRA beads
© Copyright 2025. All Rights Reserved by MedPath